Target Engagement and Cellular Fate of Otelixizumab: a Repeat Dose Escalation Study of an Anti‐cd3ε Mab in New‐onset Type 1 Diabetes Mellitus Patients
British Journal of Clinical Pharmacology（2018）
Key words
dose-response,immunoinflammation,Otelixizumab,PD,target engagement,type 1 diabetes
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined